Breast cancer

Adjuvant T-DM1 New Standard in Early HER2-Positive Breast Cancer

The standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer has evolved significantly in recent years as new agents and combinations have emerged that improve upon standard adjuvant and neoadjuvant treatment with trastuzumab alone. Patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant chemotherapy […]

Read More

Multiple myeloma cells

Daratumumab-Rd Regimen New Standard for Transplant Ineligible Myeloma

  The majority of patients with newly diagnosed multiple myeloma are treated with a triplet of bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy, followed by transplant and maintenance therapy. However, some patients, in particular the elderly, are ineligible for transplant due to frailty or comorbidities. For these patients, treatment with regimens such as VRd or […]

Read More

gut microbiome, melanoma, PD-1

Gut Microbiota Before Bone Marrow Transplantation Predicts Survival

Allogeneic hematopoietic cell transplantation (allo-HCT) is an important treatment for many hematologic malignancies. While this therapy can be life saving for some patients with hematologic cancers, it can be associated with a  complications, including infection, organ toxicity, and graft-versus-host disease (GVHD). The composition of the intestinal microbiota is a known factor influencing toxicity and outcomes […]

Read More

New Data on CAR T-Cell Therapy in Hematologic Malignancies

Chimeric antigen receptor modified (CAR) T cells have emerged in recent years as a novel and highly effective treatment option for patients with different hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). At the 2018 American Society for Hematology (ASH) Annual Meeting, new findings from several […]

Read More

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS

Anemia is a major morbidity associated with low- and intermediate-risk myelodysplastic syndrome (MDS), and patients with MDS often become dependent on red blood cell (RBC) transfusion to counteract symptoms of anemia. Luspatercept, a first-in-class erythroid-maturation agent, is involved in regulation of late stage RBC maturation and is currently being investigated as a treatment for patients […]

Read More

Ibrutinib Regimens Outperform Chemoimmunotherapy in Newly Diagnosed CLL

From December 1 to December 4, more than 25,000 attendees from around the world gathered in San Diego, California, to attend the 60th American Society for Hematology (ASH) Annual Meeting, where the latest developments and new findings in the hematology field were presented. Over the next several weeks, prIME Lines will highlight some of the […]

Read More

First-Line Avelumab Plus Axitinib Outperforms Sunitinib in RCC

For many years, the standard front-line therapy for advanced renal cell carcinoma (RCC) with clear cell histology was single-agent treatment with a vascular endothelial growth factor (VEGF) targeting tyrosine kinase inhibitor (TKI). Recently, however; immunotherapy with the PD-1 inhibitor nivolumab in combination with the CTLA-4 inhibitor ipilimumab was approved for use in patients with intermediate- […]

Read More

Atezolizumab Combo, a New First-Line Option for Advanced NSCLC

For newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations, the standard of care for many years was platinum-doublet chemotherapy. Recently, however; immunotherapy with PD-1 inhibitor pembrolizumab, either alone (for patients with PD-L1 expression over 50%) or in combination with platinum-based chemotherapy were approved as new standard for first-line treatment […]

Read More

First-Line Pembrolizumab Superior to EXTREME in Metastatic SCCHN

For years, first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has been the combination of platinum chemotherapy, 5-fluorouracil (5-FU), and cetuximab followed by cetuximab maintenance, commonly known as the EXTREME regimen. This regimen is associated with an overall survival (OS) of about 10 months. It has substantial toxicity but is […]

Read More

Local RT Improves Survival in Low Metastatic Burden Prostate Cancer

Men with newly diagnosed, metastatic prostate cancer are typically treated with systemic therapy, including androgen deprivation therapy (ADT), and receive local therapy for symptom palliation if needed. However, retrospective data suggest that local radiotherapy to the primary tumor may have an impact on survival in metastatic prostate cancer and patients with better prognoses may benefit […]

Read More